Synthesizing the Current Use of Generics in Cardiovascular Disease

Carlos Ferrario; John Flack; Henry Punzi; Domenic Sica; Daniel Wise

Synthesizing the Current Use of Generics in Cardiovascular Disease

Moderator:

Carlos M. Ferrario, MD

Wake Forest U School of Medicine

Discussants:

Date: July 16, 2012

Roundtable ID: CV11911

Citation: Med Roundtable Cardiovasc Ed. ; 3(4): 226 - 233.

Summary:
Dr. Carlos M. Ferrario from the Wake Forest University School of Medicine moderated the topic "Synthesizing the Current Use of Generics in Cardiovascular Disease" with Drs. John M. Flack from Wayne State University and the Detroit Medical Center, Henry Punzi from Punzi Medical Center and Trinity Hypertension Research Institute, Domenic Sica from Virginia Commonwealth University, Richmond, VA; and Daniel Wise from Cardiology Specialists of the Carolinas, Charlotte, NC.

The discussion focused primarily on:
1. Compliance and control rates for hypertension, dyslipidemia, and diabetes;
2. adherence to therapy and outcomes in specific patient populations;
3. effectiveness of lipid management in African Americans and Caucasians; and
4. the use of generic versus branded drugs in the management of hypertension, dyslipidemia, and the cardiometabolic syndrome.
(Med Roundtable Cardiovasc Ed. 2014;3(4):226–233)

©2014 FoxP2 Media, LLC

Compounds:
amlodipine, dihydropyridine, levothyroxine, levothyroxine sodium soft capsule, vibisone, flecainide, dofetilide, catapres, clonidine amlodipine, digoxin, Tirosint, enalapril, lisinopril, propafenone, verapamil, nadolol
Trials:
- National Health and Nutrition Examination Survey (NHANES)

Please register or login to see this content.

Please subscribe to use our print features or to download PDF files.

Open Access Content

Subscribe Now

2014 Physician Survey - Defining an Expert Clinician

Click Here for Results

"Hypertension continues to be a major contributor of cardiovascular events, and there is sufficient evidence to indicate that adequate blood pressure (BP) control is associated with marked reductions in the risk of not only target organ damage but also cardiovascular events such as stroke, myocardial infarction, and chronic renal failure."

Carlos M. Ferrario, MD

"Of the [hypertensive] people who are uncontrolled, 72% are taking 2 or fewer drugs, meaning that they’re really not intensively treated."

John M. Flack, MD, MPH

"I’ve had probably 4 anecdotal cases in the last 2 to 3 years, wherein the patients all of the sudden notice that their BP is not as controlled as it was [after refilling their prescriptions]."

Henry Punzi, MD

"For a range of drugs that require quick absorption to effect a change, you may find that a generic product is not quite as good as a branded product or different from a branded product."

Domenic Sica, MD

"I’ve had several patients come back who’ve been switched to generics that should have been relatively equivalent, and their lipid levels basically reverted to those observed without medication."

Daniel Wise, MD